PMID: 7542531Mar 1, 1995Paper

Regulation of prostaglandin production by nitric oxide; an in vivo analysis

British Journal of Pharmacology
D SalveminiP Needleman

Abstract

1. Endotoxin E. Coli lipopolysaccharide (LPS)-treatment in conscious, restrained rats increased plasma and urinary prostaglandin (PG) and nitric oxide (NO) production. Inducible cyclo-oxygenase (COX-2) and nitric oxide synthase (iNOS) expression accounted for the LPS-induced PG and NO release since the glucocorticoid, dexamethasone inhibited both effects. Thus, LPS (4 mg kg-1) increased the plasma levels of nitrite/nitrate from 14 +/- 1 to 84 +/- 7 microM within 3 h and this rise was inhibited to 35 +/- 1 microM by dexamethasone. Levels of 6-keto PGF1 alpha in the plasma were below the detection limit of the assay (< 0.2 ng ml-1). However, 3 h after the injection of LPS these levels rose to 2.6 +/- 0.2 ng ml-1 and to 0.7 +/- 0.01 ng ml-1 after LPS in rats that received dexamethasone. 2. The induced enzymes were inhibited in vivo with selective COX and NOS inhibitors. Furthermore, NOS inhibitors, that did not affect COX activity in vitro markedly suppressed PG production in the LPS-treated animals. For instance, the LPS-induced increased in plasma nitrite/nitrate and 6-keto PGF1 alpha at 3 h was decreased to 18 +/- 2 microM and 0.5 +/- 0.02 ng ml-1, 23 +/- 1 microM and 0.7 +/- 0.01 ng ml-1, 29 +/- 2 microM and 1 +/- 0.01 ng ml-1...Continue Reading

References

Nov 1, 1992·Kidney International·A JansenH T Cook
Dec 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·V RettoriS M McCann
Jan 1, 1992·Cardiovascular Research·C E WrightS Moncada
May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J L MasferrerP Needleman
Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M W RadomskiS Moncada
Sep 3, 1991·Klinische Wochenschrift·T F Lüscher, H A Bock
May 8, 1991·Biochimica Et Biophysica Acta·D L DeWitt
Oct 1, 1990·The Journal of Clinical Investigation·J L MasferrerP Needleman
Dec 1, 1990·Kidney International·V CattellS Moncada
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·D SalveminiJ Vane
Dec 30, 1993·The New England Journal of Medicine·S Moncada, A Higgs
Oct 1, 1993·Analytical Biochemistry·T P MiskoM G Currie
Nov 15, 1993·Biochemical and Biophysical Research Communications·S LiuT W Evans
Nov 1, 1993·British Journal of Pharmacology·M J GriffithsT W Evans
May 1, 1994·The Journal of Clinical Investigation·D SalveminiP Needleman
Mar 16, 1993·European Journal of Pharmacology·T P MiskoM G Currie
Aug 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·D SalveminiP Needleman
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·J L MasferrerK Seibert
Jul 15, 1993·Biochemical and Biophysical Research Communications·T InoueT Ogihara

❮ Previous
Next ❯

Citations

Sep 22, 2001·Electrophoresis·J StulíkP R Jungblut
Feb 24, 2001·BioFactors·K WatanabeK Wakabayashi
Nov 1, 1996·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·M R Forwood
Jan 4, 2012·Journal of Neural Transmission·Mahesh Ramalingam, Sung-Jin Kim
May 30, 1998·Biochemical Pharmacology·L SautebinM Di Rosa
Nov 8, 2002·European Journal of Pharmacology·Hans GühringKay Brune
May 7, 1998·European Journal of Pharmacology·B Y De WinterP A Pelckmans
Jul 17, 1999·European Journal of Pharmacology·H MatsudaM Yoshikawa
Apr 25, 2000·Toxicon : Official Journal of the International Society on Toxinology·M L GuzzoS B Mello
Oct 2, 2001·Prostaglandins & Other Lipid Mediators·G Basini, C Tamanini
Mar 18, 2000·Neuroscience Research·N Yonehara, M Yoshimura
Feb 13, 1999·Progress in Neurobiology·M J Millan
Jan 25, 2003·Burns : Journal of the International Society for Burn Injuries·Martin G Schwacha
May 20, 1998·Nutrition·B Alexander
May 29, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Bahar TunçtanNurettin Abacioglu
Dec 14, 2006·Prostaglandins & Other Lipid Mediators·Rita K UpmacisDavid P Hajjar
Jun 2, 1998·Environmental Toxicology and Pharmacology·A G LjungmanC Tagesson
Jun 11, 2002·British Journal of Pharmacology·José C da S RochaFrancisco A C da Rocha
Aug 8, 2002·Journal of Gastroenterology and Hepatology·Gu KongJong Chul Rhee
Jun 9, 2001·Antioxidants & Redox Signaling·D Pérez-Sala, S Lamas
Apr 29, 1999·Current Opinion in Obstetrics & Gynecology·R J Sawdy, P R Bennett
Oct 19, 2001·Journal of Clinical Gastroenterology·H J SonJ C Rhee
Sep 7, 2001·Transplantation·S C WeightM L Nicholson
Jan 1, 1996·Fundamental & Clinical Pharmacology·M Pairet, G Engelhardt
Jan 1, 1996·Fundamental & Clinical Pharmacology·Z Fatehi-HassanabadJ C Stoclet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.